1.Dystrophic Calcification and Stone Formation on the Entire Bladder Neck After Potassium-titanyl Phosphate Laser Vaporization for the Prostate: A Case Report.
Sang Wohn JEON ; Yong Koo PARK ; Sung Goo CHANG
Journal of Korean Medical Science 2009;24(4):741-743
Dystrophic calcification can be defined as a calcification that occurs in degenerated or necrotic tissue. It is associated with multiple clinical conditions, such as collagen vascular diseases. It involves the deposition of calcium in soft tissues despite no generalized disturbance in the calcium or phosphorus metabolism, and this is often seen at sites of previous inflammation or damage. Potassium-titanyl phosphate (KTP) laser vaporization of the prostate is safe and relatively bloodless procedure that results in a shorter catheterization, immediate symptomatic improvement, and less severe postoperative irritative symptoms. However, longer follow-up studies or reports about complications are lacking. Here in we report a case of dystrophic calcification and stone formation on the entire bladder neck after performing KTP laser vaporization of benign prostate hyperplasia. That was treated by lithotripsy and transurethral resection.
Aged
;
Calcinosis/*diagnosis/pathology
;
Humans
;
Lasers, Solid-State/*adverse effects
;
Lithotripsy
;
Male
;
Prostatic Hyperplasia/*surgery
;
Urinary Bladder Calculi/*diagnosis/etiology/ultrasonography
;
Urinary Bladder Diseases/*diagnosis/etiology/ultrasonography
2.The Role of Metastasectomy and Immunochemotherapy in Multimodal Therapy for Metastatic Renal Cell Carcinoma.
Sang Wohn CHON ; Seung Hyun JEON ; Sung Goo CHANG
Korean Journal of Urology 2008;49(1):1-6
PURPOSE: One third of renal cell caricinoma(RCC) patients present with metastatic disease and 20-40% of these patients who undergo nephrectomy for clinically localized RCC will develop metastases. Eventually, the number of those patients who develop metastatic disease will increase to 30-50%. The aim of this study is to compare the efficacy and survival rate in relation to the time of performing metastasectomy and immnuochemotherapy. MATERIALS AND METHODS: We retrospectively enrolled 12 patients who had undergone radical nephrectomy, immunochemotherapy and metastasectomy between 1998 and 2007. The patients were subdivided into two groups. Group 1 included the patients who received radical nephrectomy, metastasectomy and immunochemotherapy altogether. Group 2 included the patients who developed metachronous metastases during follow-up after radical nephrectomy and so they then underwent metastasectomy and immunochemotherapy. We compared the survival rates between the two groups. RESULTS: The sites of initial metastasis were found to be 8 cases of lung metastasis, 2 of bone metastasis, 1 of brain metastasis and 1 of colon metastasis. The 5-year survival rate of the 5 patients from group 1 was 37.5%. In group 2, the 5-year survival rate of the 7 patients was 71.4% and the disease-free mean interval between primary resection of the kidney and metastasectomy was 36.43+/-7.62 months. Statistically, there was no significant difference of survival rates between the two groups. CONCLUSIONS: The results of this study suggest that metastasectomy followed by radical nephrectomy results in a longer survival time for the patients with metastatic cancer than that of patient that undergo radical nephretomy, metastasectomy and immunotherapy at the same time. We can recommend metastasetomy any time for the RCC patients who have technical resectable metastases with possibly positive prognostic factors and a good functional condition.
Brain
;
Carcinoma, Renal Cell
;
Colon
;
Follow-Up Studies
;
Humans
;
Immunotherapy
;
Kidney
;
Lung
;
Metastasectomy
;
Neoplasm Metastasis
;
Nephrectomy
;
Retrospective Studies
;
Survival Rate